date,title,source
Oct-18-18,Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell Therapy,GlobeNewswire
Oct-29-18,Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer,GlobeNewswire
Oct-31-18,Edited Transcript of NTLA earnings conference call or presentation 31-Oct-18 12:00pm GMT,Thomson Reuters StreetEvents
Oct-31-18,Cambridge's Intellia delays gene editing trial,American City Business Journals
Oct-31-18,"Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates",Zacks
Nov-01-18,Edited Transcript of NTLA earnings conference call or presentation 31-Oct-18 12:00pm GMT,Thomson Reuters StreetEvents
Nov-05-18,Here's Why CRISPR Stocks Fell as Much as 40.7% in October,Motley Fool
Nov-05-18,Edited Transcript of NTLA earnings conference call or presentation 31-Oct-18 12:00pm GMT,Thomson Reuters StreetEvents
Nov-06-18,Edited Transcript of NTLA earnings conference call or presentation 31-Oct-18 12:00pm GMT,Thomson Reuters StreetEvents
Nov-07-18,Cambridge's Editas asks FDA to start gene editing trial,American City Business Journals
Nov-07-18,Edited Transcript of NTLA earnings conference call or presentation 31-Oct-18 12:00pm GMT,Thomson Reuters StreetEvents
Nov-07-18,"Consolidated Research: 2018 Summary Expectations for STORE Capital, Ares Commercial Real Estate, Intellia Therapeutics, City Office REIT, RealPage, and Data I/O  Fundamental Analysis, Key Performance Indications",GlobeNewswire
Nov-08-18,Intellia Therapeutics to Present at November Healthcare Investor Conferences,GlobeNewswire
Nov-26-18,"With genetically edited babies, a scientist transgresses a moral boundary",MarketWatch
Nov-26-18,Mass. biotech leaders voice alarm over report of first gene-edited babies,American City Business Journals
Nov-28-18,Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns',Benzinga
Nov-30-18,This Biotech Stock Could Launch Its First CRISPR Drug In 2022,Investor's Business Daily
Nov-30-18,Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018,Motley Fool
Nov-30-18,The Market is All Packed for Buenos Aires,Zacks
Dec-06-18,Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population,GlobeNewswire
Dec-10-18,Why CRSP Stock Has Added Layers of Risk,InvestorPlace
Dec-17-18,"New Research: Key Drivers of Growth for Ashland Global, Intellia Therapeutics, Thor Industries, Zogenix, BWX Technologies, and Heidrick & Struggles International  Factors of Influence, Major Initiatives and Sustained Production",GlobeNewswire
Jan-04-19,These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy,Investor's Business Daily
Jan-07-19,"Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag",Zacks
Jan-10-19,"The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29%",Motley Fool
Jan-11-19,Here's Why Intellia Therapeutics Stock Lost 23.8% in December,Motley Fool
Jan-22-19,Editas CEO Resigns  Sending All 3 CRISPR Stocks Into Free Fall,Investor's Business Daily
Jan-24-19,"Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors",GlobeNewswire
Feb-01-19,German firm that serves gene therapy biotechs opens Cambridge HQ,American City Business Journals
Feb-01-19,3 Biotech Stocks That Are Set for a Breakthrough,InvestorPlace
Feb-06-19,"Research Report Identifies Norfolk Southern, DENTSPLY SIRONA, Healthcare Realty Trust, PTC, Intellia Therapeutics, and El Paso Electric with Renewed Outlook  Fundamental Analysis, Calculating Forward Movement",GlobeNewswire
Feb-26-19,CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study,Zacks
Feb-28-19,Intellia CEO not involved in Starboard's Bristol-Myers board challenge,Reuters
Feb-28-19,Intellia CEO not involved in Starboard's Bristol-Myers board challenge,Reuters
Mar-01-19,Intellia CEO not involved in Starboard's Bristol-Myers board challenge,Reuters
Mar-01-19,Intellia CEO not involved in Starboard's Bristol-Myers board challenge,Reuters
Mar-07-19,5 Top Gene-Editing Stocks for 2019,Motley Fool
Mar-12-19,Some Intellia Therapeutics (NASDAQ:NTLA) Shareholders Have Copped A Big 50% Share Price Drop,Simply Wall St.
Apr-03-19,CRISPR Biotech Inks Deal To Use Stem Cells In Gene-Editing Medicine,Investor's Business Daily
Apr-09-19,These Cannabis and China ETFs are Leading the 2019 Rally,Investopedia
Apr-15-19,Intellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy,GlobeNewswire
Apr-17-19,One-Size-Fits-All CRISPR Lock Could Catapult the Sector Forward,GuruFocus.com
Apr-17-19,"Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag",Zacks
Apr-25-19,Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update,GlobeNewswire
Apr-29-19,Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy,GlobeNewswire
May-02-19,"Intellia Therapeutics, Inc. (NTLA) Q1 2019 Earnings Call Transcript",Motley Fool
May-02-19,"Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates",Zacks
May-02-19,Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update,GlobeNewswire
May-07-19,Edited Transcript of NTLA earnings conference call or presentation 2-May-19 12:00pm GMT,Thomson Reuters StreetEvents
May-09-19,"Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy?",Insider Monkey
